Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/11/047725
CTRI/2022/11/047725
Not Yet Recruiting
N/A

Efficacy and Safety of addition of Dapagliflozin to conventional therapy in patients of Heart Failure with Mildly Reduced and Preserved Ejection Fraction: A placebo controlled double blind study

Sanjay Kumar R0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Sanjay Kumar R
Status
Not Yet Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Sanjay Kumar R

Eligibility Criteria

Inclusion Criteria

  • •1\.Patients willing singned informed consent
  • •2\.Patients with documented diagnosis of HFpEF and HFmrEF with medical history of symptoms and signs of Heart Failure
  • •3\.Patients with LVEF 40\-60% or evidence of structural Heat disease

Exclusion Criteria

  • •1\.Patients who are not willing to sign informed consent.
  • •2\.Patients with LVEF \<40%
  • •3\.Patients with eGFR \<25ml/min/1\.73m3
  • •4\.Patients who are intolerance to Dapagliflozin

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
N/A
Benefits and side effects of Dapagliflozin medicine in diabetic patients with kidney disease.
CTRI/2022/09/045596Maulana Azad Medical College Delhi
Not Yet Recruiting
N/A
Dapagliflozin is a licensed medicine used for reducing blood sugar in people with diabetes and this study will test whether it can also reduce the stiffness in the liver which commonly occurs in diabetes.Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
CTRI/2019/05/019286Dr Shashi Panicker
Recruiting
N/A
Examination of the efficacy of dapagliflozin in patients with type 2 diabetesType 2 diabetes
JPRN-UMIN000021954Tonami general hospital Department of diabetes mellitus and endocrinology200
Not Yet Recruiting
N/A
A clinical trial to compare the efficacy of combination therapy of antidiabetic drugs dapagliflozin & metformin versus metformin alone in improving metabolic profile in overweight & obese women with polycystic ovary syndrome.Health Condition 1: E888- Other specified metabolic disordersHealth Condition 2: E66- Overweight and obesity
CTRI/2023/06/054098Dr Vishal Agarwal
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-003897-41-PLAstraZeneca AB4,500